Logo image of HIVE

HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

NASDAQ:HIVE - Nasdaq - CA4339211035 - Common Stock - Currency: USD

2.49  -0.2 (-7.43%)

After market: 2.53 +0.04 (+1.61%)

Fundamental Rating

4

Taking everything into account, HIVE scores 4 out of 10 in our fundamental rating. HIVE was compared to 284 industry peers in the Software industry. HIVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HIVE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year HIVE has reported negative net income.
In the past year HIVE has reported a negative cash flow from operations.
In multiple years HIVE reported negative net income over the last 5 years.
Each year in the past 5 years HIVE had a positive operating cash flow.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

The Return On Assets of HIVE (-4.43%) is comparable to the rest of the industry.
HIVE has a Return On Equity (-5.30%) which is in line with its industry peers.
Industry RankSector Rank
ROA -4.43%
ROE -5.3%
ROIC N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HIVE has been increased compared to 1 year ago.
HIVE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HIVE has an improved debt to assets ratio.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

HIVE has an Altman-Z score of 3.22. This indicates that HIVE is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HIVE (3.22) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.08 indicates that HIVE is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.08, HIVE perfoms like the industry average, outperforming 53.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 3.22
ROIC/WACCN/A
WACC12.61%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.56 indicates that HIVE has no problem at all paying its short term obligations.
HIVE has a Current ratio of 5.56. This is amongst the best in the industry. HIVE outperforms 89.49% of its industry peers.
HIVE has a Quick Ratio of 5.56. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a better Quick ratio (5.56) than 89.49% of its industry peers.
Industry RankSector Rank
Current Ratio 5.56
Quick Ratio 5.56
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

HIVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.85%, which is quite impressive.
The Revenue has been growing slightly by 7.66% in the past year.
The Revenue has been growing by 29.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)84.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)7.66%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%

3.2 Future

HIVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.81% yearly.
HIVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.69% yearly.
EPS Next Y58.41%
EPS Next 2Y24.54%
EPS Next 3Y41.81%
EPS Next 5YN/A
Revenue Next Year1.5%
Revenue Next 2Y48.62%
Revenue Next 3Y61.69%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HIVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HIVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HIVE is valued cheaper than 99.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.23
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

HIVE's earnings are expected to grow with 41.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.54%
EPS Next 3Y41.81%

More info and screens

0

5. Dividend

5.1 Amount

HIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (2/21/2025, 8:25:39 PM)

After market: 2.53 +0.04 (+1.61%)

2.49

-0.2 (-7.43%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)06-23 2025-06-23/bmo
Inst Owners23.92%
Inst Owner Change-64.64%
Ins Owners0.42%
Ins Owner Change0%
Market Cap368.69M
Analysts80
Price Target5.33 (114.06%)
Short Float %3.66%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.97%
Min EPS beat(2)43.42%
Max EPS beat(2)48.51%
EPS beat(4)4
Avg EPS beat(4)69.13%
Min EPS beat(4)43.42%
Max EPS beat(4)93.17%
EPS beat(8)5
Avg EPS beat(8)-41.12%
EPS beat(12)7
Avg EPS beat(12)-165.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.5%
Min Revenue beat(2)-8.08%
Max Revenue beat(2)17.08%
Revenue beat(4)3
Avg Revenue beat(4)6.75%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)17.08%
Revenue beat(8)6
Avg Revenue beat(8)7.33%
Revenue beat(12)9
Avg Revenue beat(12)19.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)-0.8%
EPS NQ rev (1m)-4.76%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)22.22%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)-1.98%
Revenue NY rev (1m)3.73%
Revenue NY rev (3m)2.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA 0.23
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.83
BVpS1.89
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.43%
ROE -5.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA 0.93
Cap/Depr 118.01%
Cap/Sales 60.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.56
Quick Ratio 5.56
Altman-Z 3.22
F-Score5
WACC12.61%
ROIC/WACCN/A
Cap/Depr(3y)132.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.57%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y58.41%
EPS Next 2Y24.54%
EPS Next 3Y41.81%
EPS Next 5YN/A
Revenue 1Y (TTM)7.66%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%
Revenue Next Year1.5%
Revenue Next 2Y48.62%
Revenue Next 3Y61.69%
Revenue Next 5YN/A
EBIT growth 1Y38.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.19%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.49%
OCF growth 3Y-17.04%
OCF growth 5YN/A